Our top pick for
Building a portfolio
CEL-SCI Corporation is a biotechnology business based in the US. CEL-SCI Corporation shares (CVM) are listed on the NYSE MKT and all prices are listed in US Dollars.
|Latest market close||USD$14.31|
|52-week range||USD$7.36 - USD$18|
|50-day moving average||USD$12.8732|
|200-day moving average||USD$13.326|
|Wall St. target price||USD$23|
|Dividend yield||N/A (0%)|
|Earnings per share (TTM)||USD$-1.124|
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
|1 week (2021-01-15)||0.28%|
|1 month (2020-12-23)||6.71%|
|3 months (2020-10-22)||4.00%|
|6 months (2020-07-22)||8.99%|
|1 year (2020-01-22)||4.15%|
|2 years (2019-01-22)||435.96%|
|3 years (2018-01-22)||550.45%|
|5 years (2016-01-22)||2,881.25%|
|Gross profit TTM||USD$-12,196,533|
|Return on assets TTM||-46.11%|
|Return on equity TTM||-293.41%|
|Market capitalisation||USD$509.3 million|
TTM: trailing 12 months
There are currently 10.2 million CEL-SCI Corporation shares held short by investors – that's known as CEL-SCI Corporation's "short interest". This figure is 1.1% down from 10.3 million last month.
There are a few different ways that this level of interest in shorting CEL-SCI Corporation shares can be evaluated.
CEL-SCI Corporation's "short interest ratio" (SIR) is the quantity of CEL-SCI Corporation shares currently shorted divided by the average quantity of CEL-SCI Corporation shares traded daily (recently around 558832.05689278). CEL-SCI Corporation's SIR currently stands at 18.28. In other words for every 100,000 CEL-SCI Corporation shares traded daily on the market, roughly 18280 shares are currently held short.
However CEL-SCI Corporation's short interest can also be evaluated against the total number of CEL-SCI Corporation shares, or, against the total number of tradable CEL-SCI Corporation shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case CEL-SCI Corporation's short interest could be expressed as 0.26% of the outstanding shares (for every 100,000 CEL-SCI Corporation shares in existence, roughly 260 shares are currently held short) or 0.2681% of the tradable shares (for every 100,000 tradable CEL-SCI Corporation shares, roughly 268 shares are currently held short).
A SIR above 10% would generally be considered pretty high, pointing to a potentially pessimistic outlook for the share price and a discouraging interest in betting against CEL-SCI Corporation.
Find out more about how you can short CEL-SCI Corporation stock.
We're not expecting CEL-SCI Corporation to pay a dividend over the next 12 months.
CEL-SCI Corporation's shares were split on a 1:25 basis on 15 June 2017. So if you had owned 25 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your CEL-SCI Corporation shares – just the quantity. However, indirectly, the new 2400% higher share price could have impacted the market appetite for CEL-SCI Corporation shares which in turn could have impacted CEL-SCI Corporation's share price.
Over the last 12 months, CEL-SCI Corporation's shares have ranged in value from as little as $7.36 up to $18. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NYSE MKT average) beta is 1, while CEL-SCI Corporation's is 2.1958. This would suggest that CEL-SCI Corporation's shares are significantly more volatile than the average for this exchange and represent a higher risk.
CEL-SCI Corporation engages in the research and development of immunotherapy for the treatment of cancer and other diseases. The company's lead investigational immunotherapy is Multikine, which is under phase III clinical trial for the treatment of primary head and neck cancer. Its Ligand Epitope Antigen Presentation System, a pre-clinical patented T-cell modulation process that stimulates the human immune system to fight bacterial, viral, and parasitic infections, as well as autoimmune diseases, allergies, transplantation rejections, and cancer. The company also develops LEAPS-H1N1-DC, a product candidate for the treatment of pandemic influenza in hospitalized patients; and CEL-2000 and CEL-4000 vaccine product candidates for the treatment of rheumatoid arthritis. CEL-SCI Corporation has a collaboration agreement with the University of Georgia's Center for Vaccines and Immunology to develop LEAPS COVID-19 immunotherapy. The company was founded in 1983 and is headquartered in Vienna, Virginia.
Steps to owning and managing SSNC, with 24-hour and historical pricing before you buy.
Steps to owning and managing SMBC, with 24-hour and historical pricing before you buy.
Steps to owning and managing SMED, with 24-hour and historical pricing before you buy.
Steps to owning and managing SJW, with 24-hour and historical pricing before you buy.
Steps to owning and managing SFBS, with 24-hour and historical pricing before you buy.
Steps to owning and managing LEDS, with 24-hour and historical pricing before you buy.
Steps to owning and managing SC, with 24-hour and historical pricing before you buy.
Steps to owning and managing RTW, with 24-hour and historical pricing before you buy.
Steps to owning and managing RIVE, with 24-hour and historical pricing before you buy.
Steps to owning and managing RVSB, with 24-hour and historical pricing before you buy.
finder.com is an independent comparison platform and information service that aims to provide you with the tools you need to make better decisions. While we are independent, the offers that appear on this site are from companies from which finder.com receives compensation. We may receive compensation from our partners for placement of their products or services. We may also receive compensation if you click on certain links posted on our site. While compensation arrangements may affect the order, position or placement of product information, it doesn't influence our assessment of those products. Please don't interpret the order in which products appear on our Site as any endorsement or recommendation from us. finder.com compares a wide range of products, providers and services but we don't provide information on all available products, providers or services. Please appreciate that there may be other options available to you than the products, providers or services covered by our service.